UPDATE 1-Alnylam's rare genetic disorder drug gets early U.S. approval

Alnylam Pharmaceuticals Inc on Wednesday received an early U.S. approval for its gene silencing drug to treat patients with a rare genetic disorder that can cause severe pain. The drug, Givlaari, uses a mechanism known as RNA interference to target and “silence” specific genetic material, blocking the production of the protein that causes the disease called acute hepatic porphyria. …read more

Source:: Yahoo Finance

      

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.